Zobrazeno 1 - 10
of 94
pro vyhledávání: '"Mary M. Ryan"'
Publikováno v:
Annals of Clinical and Translational Neurology, Vol 8, Iss 8, Pp 1646-1655 (2021)
Abstract Objectives Preclinical Alzheimer’s disease (AD) clinical trials screen cognitively unimpaired older adults for biomarker criteria and disclose their results. We examined whether participants in the Anti‐Amyloid Treatment in Asymptomatic
Externí odkaz:
https://doaj.org/article/972d22bd0bdb49c3a8dfdf6ebd874ae0
Autor:
Mary M. Ryan, Joshua D. Grill, Daniel L. Gillen, for the Alzheimer’s Disease Neuroimaging Initiative
Publikováno v:
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-8 (2019)
Abstract Background Preclinical Alzheimer’s disease (AD) clinical trials require participants to enroll with a study partner, a person who can attend visits and report changes in the participant’s cognitive ability. Whether study partners, compar
Externí odkaz:
https://doaj.org/article/1cea0af117a94ed29a17c06a3046598d
Autor:
Mary M. Ryan, Daniel L. Gillen
Publikováno v:
The Annals of Applied Statistics. 17
Publikováno v:
Alzheimer's & Dementia. 18
Publikováno v:
Statistics in Medicine. 39:1941-1951
We present a methodology motivated by a controlled trial designed to validate SPOT GRADE, a novel surgical bleeding severity scale. Briefly, the study was designed to quantify inter- and intra-surgeon agreement for characterizing the severity of surg
Autor:
Joshua D. Grill, Dan Hoang, Megan G. Witbracht, Mary M Ryan, Chelsea G. Cox, Daniel L. Gillen
Publikováno v:
Alzheimer disease and associated disorders, vol 35, iss 2
Alzheimer Dis Assoc Disord
Alzheimer Dis Assoc Disord
Introduction The apolipoprotein E (APOE) gene is the strongest known genetic risk factor for sporadic Alzheimer disease (AD). APOE can be used as an enrichment strategy or inclusion criterion for AD prevention trials. Personal genomics companies mark
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::32902538a1d34a2782f291b8ba57ab34
https://escholarship.org/uc/item/2301k8sp
https://escholarship.org/uc/item/2301k8sp
Publikováno v:
J Prev Alzheimers Dis
The journal of prevention of Alzheimer's disease, vol 8, iss 1
The journal of prevention of Alzheimer's disease, vol 8, iss 1
Background: Preclinical Alzheimer’s disease clinical trials test candidate treatments in individuals with biomarker evidence but no cognitive impairment. Participants are required to co-enroll with a knowledgeable study partner, to whom biomarker i
Publikováno v:
Alzheimer's Research & Therapy
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-8 (2019)
Alzheimer’s Research & Therapy, Vol 11, Iss 1, Pp 1-8 (2019)
Background Preclinical Alzheimer’s disease (AD) clinical trials require participants to enroll with a study partner, a person who can attend visits and report changes in the participant’s cognitive ability. Whether study partners, compared to par
Publikováno v:
The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, vol 27, iss 3
Objective All Alzheimer disease (AD) clinical trials, including those enrolling patients with mild cognitive impairment (MCI), require dyadic participation. The purpose of this study was to elucidate how people with MCI and their study partners decid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9fa66bce435f658e8e33a586056f8bad
https://europepmc.org/articles/PMC6387840/
https://europepmc.org/articles/PMC6387840/
Publikováno v:
Alzheimer's & Dementia. 15:P788-P789